Daiichi Sankyo To Start Phase III Nimotuzumab Trials In Japan For Gastric, Lung Cancer
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo will start Phase III trials of recombinant humanized IgG1 monoclonal antibody nimotuzumab for treatment of patients with lung squamous cell carcinoma and gastric cancer in Japan.
You may also be interested in...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.